Giannis Mountzios, Director of 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, shared on LinkedIn:
“Truly honored that our work has been selected for presentation at the Presidential Symposium 1 of the World Lung Cancer Conference (WCLC26) in Seoul on Sunday, September 13:
Primary analysis of the global, randomized phase III EVOKE-03/KEYNOTE D46 clinical trial on the combination of Sacituzumab Govitecan plus pembro vs pembro monotherapy in patients with advanced NSCLC and PDL1 expression >=50%.
Thank you International Association for the Study of Lung Cancer for selecting a negative phase III trial (by press release) for the Presidential Symposium, those data are important to be shared and communicated in detail, because they can create food for thought and be hypothesis generating for future trials.
Looking forward to the discussion that will follow, especially in he context of the Optitrop Lung 05 results.
Time: Sunday, 13 September 08:00-10:30 KST
Place: Presidential Symposium 1
Plenary, Hall D2, 3F”
Giannis Mountzios was recognized among OncoDaily’s ‘Top 100 Xfluencers in Lung Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024’, highlighting their contributions to the field of oncology.
Nominations for ‘100 Influential People in Oncology 2026’ are now open, recognizing leaders, researchers, clinicians, innovators, advocates, and other individuals making a meaningful impact on oncology and cancer care.
Don’t miss the opportunity to nominate yourself, a colleague, or someone whose contributions deserve to be recognized.
Submit Your Nomination by September 15.
